Someone hears that a peptide 'stimulates growth hormone' and asks the obvious question: if it works, why isn't it sold at the pharmacy next to the vitamins? It's a fair question, and the short answer involves regulation as much as science. Growth hormone secretagogues sit in a gray zone that confuses many readers, so this post explains what they are, which families you'll hear about, what a registered medicine has to prove, and how to judge a claim without taking it on faith.

The pituitary gland releases growth hormone (GH) in pulses rather than at a steady rate. That rhythm matters for everything that follows, because a substance that touches GH release can act in several different ways. Keep that in mind as you read.

What a GH secretagogue actually does

A growth hormone secretagogue is a substance that prompts the body to release its own GH. It is not GH itself. The distinction matters because these molecules act upstream, on the signaling system that tells the pituitary when to let GH out.

There are two main pathways. One uses the receptor for growth hormone-releasing hormone (GHRH), the hypothalamic signal that tells the pituitary to secrete GH. The other uses the growth hormone secretagogue receptor (GHSR-1a), which is also the receptor that ghrelin, the hormone linked to hunger, activates. Both routes end at the same gland, but they reach it by different doors.

Stimulating release is not the same as raising GH in a sustained way or producing a proven clinical effect. Somatostatin, another hypothalamic hormone, acts as a brake on GH release. GH also drives the liver to produce IGF-1, and IGF-1 feeds back to dampen further release. So the system pushes back. When you read a study, ask whether it measured GH pulses, total GH, IGF-1, or a real clinical outcome such as body composition or physical function. Those are different questions with different answers.

The families you'll hear about

Man working at a microscope in a laboratory

Sermorelin and tesamorelin are GHRH analogs, meaning they mimic the natural releasing signal. Tesamorelin is the one with an approved label. In the United States, it is approved to reduce excess abdominal fat in people with HIV-associated lipodystrophy, a specific condition. That narrow indication is the exception in this group, and it does not extend to general use. Sermorelin was once licensed in the United States, but it is no longer marketed there as a registered medicine. Check the current status with the FDA before assuming anything about it.

GHRP-6 and GHRP-2 were among the first ghrelin-receptor agonists studied in humans. Their effects on appetite are well described in the literature, which is one reason they show up so often in discussions about this class. Ipamorelin is often described as more selective, meaning it tends to raise GH with less effect on other hormones in the studies that have examined it. Hexarelin is a potent GHRP with a side effect profile described in trials. Neither ipamorelin nor hexarelin has an approved indication in the United States or the European Union.

MK-677, also called ibutamoren, is the oral option most people ask about. It has been tested in clinical trials, and those trials reported effects on appetite, fluid retention, and blood glucose and insulin sensitivity. It was studied seriously enough to appear in the scientific literature, yet it never became an approved medicine. A molecule can be studied for years and still not reach a label.

What 'registered medicine' really requires

Clinical trials move through phases. Phase I focuses mainly on safety and on how the body handles the drug in a small group of volunteers. Phase II explores dose and preliminary efficacy. Phase III compares the drug against placebo or a standard treatment in larger groups, usually over a longer period. The FDA describes this process in its clinical research guidance, and it's worth reading that page once to see how each stage builds on the last.

The endpoints matter as much as the phases. A rise in IGF-1 is a biomarker, and biomarkers are useful, but regulators generally want outcomes that matter to patients, such as symptoms, function, or disease progression. They also want results replicated across more than one well-designed study, not a single promising report.

Manufacturing is a separate hurdle. Good manufacturing practice (GMP) requires control of identity, purity, potency, stability, and batch traceability. A molecule can show a real effect in a trial and still be rejected if it cannot be produced consistently. ANVISA publishes its requirements for medicine registration and good manufacturing practice in Brazil, and the same logic runs through most regulatory systems.

After approval, pharmacovigilance continues. Adverse events are collected, monitored, and acted on. It helps to keep three ideas apart. Approval is the decision that a product meets the standard for a specific use. Registration is the legal authorization for that product to be sold in a given country. Off-label use means a registered drug is prescribed for something outside its approved indication, dosage, or population. Off-label use is a clinical practice, not a sign that the product was evaluated for that purpose. Definitions can vary, so check the current rules in your country.

Why most of them never reach a registered label

Many early studies of these compounds are small, short, or limited to a narrow population. A small study in one group says little about older adults, women, people with other health conditions, or anyone outside the trial. Limited scope doesn't make a finding false, but it does limit how far the finding can travel.

Sponsors also stop programs for many reasons: commercial priorities, a safety signal, or efficacy that doesn't hold up. ClinicalTrials.gov lists trial records with statuses such as completed, suspended, or terminated. Search it for MK-677 and ipamorelin, then open the records and read the stated reason for any termination. That single step tells you more than most online summaries.

Studies do report effects on blood glucose, insulin sensitivity, fluid retention, and appetite. Those findings matter, especially for anyone with diabetes or prediabetes. However, nobody has a definitive answer on long-term risk, and the absence of evidence is not the same as evidence of safety.

The unregulated market adds another layer. Products labeled 'for research use only' may not have verified purity or content, and health agencies, including the FDA, have warned about unapproved and mislabeled products sold online. That label does not replace regulatory review. Some suppliers, PeptPro among them, state a product's intended purpose and origin more clearly than many sellers do. That transparency is useful, but it is not the same as a sanitary registration, and it does not show that a product was made to medicine standards.

Sport, doping rules, and why the label matters

The World Anti-Doping Agency (WADA) includes growth hormone secretagogues on its prohibited list, within the section covering peptide hormones and related substances. The list names GH-releasing factors and GH secretagogues, a group that includes ghrelin mimetics such as GHRPs and MK-677. The current version of the list is the one that counts, so check it before any competition season.

Athletes can test positive without intending to. Contamination in a product or a label that leaves out an ingredient can be enough, and under the WADA Code, athletes carry responsibility for what is found in their samples. Reading a supplier's certificate of analysis, such as the documentation PeptPro makes available on its site (https://peptpro.app), can help you check what you're actually buying. That document still does not replace the judgment of a sports physician or anti-doping advisor who follows your specific case.

Rules don't stop at WADA. Some national federations, amateur competitions, and gyms have their own policies, and they may be stricter than the global list. If you compete at any level, look up your federation's rules directly rather than relying on a forum thread.

How to judge a claim and what to bring to a doctor

Before you believe a promise about any peptide, ask four questions. What phase is the study? Who was studied? What outcome was measured? Who paid for the work? A glossy claim often falls apart once you answer these, and a good study will usually make the answers easy to find in its abstract or methods.

Pay attention to the population too. Animal data, healthy human volunteer data, and data from patients with a specific condition are three different tiers of evidence. Animal results may not translate to people. Healthy volunteers can tell you about safety and how a drug behaves in the body, but not necessarily whether it helps with a health problem. Frameworks such as GRADE rate the certainty of evidence by looking at study design, consistency across studies, precision, and other factors, which is a useful way to think about how much weight a finding deserves.

If you're thinking about discussing these compounds with a clinician, bring organized information. PeptPro can help you put your questions in order before the appointment, though the conversation with a qualified professional is the step that matters most. Bring the following:

A complete list of every product you have taken or are considering, with doses as written on the label
Where each product came from, including the supplier and any documentation you received
Baseline tests, such as IGF-1 and blood glucose, if your doctor thinks they are needed
Your full health history, including medications, prior conditions, and family history

Research on most of these compounds is still limited, and no study can promise a specific result for any individual. Any decision about use should follow a personal assessment with a clinician who knows your health history.

FAQ

Are peptides FDA approved?

Some peptide drugs are approved for specific conditions, but many peptides sold online as research compounds are not. Approval applies to a particular product, for particular uses, with a particular label. You can search the FDA's Drugs@FDA database to check any product.

Is sermorelin a registered medicine?

Sermorelin was once licensed in the United States but is no longer marketed there as a registered medicine. Check the current status with the FDA and your country's regulator, because the situation can differ elsewhere.

Is MK-677 legal?

Legal status depends on the country and the context of use. MK-677 has never become an approved medicine, and it is on the WADA prohibited list, so athletes subject to anti-doping rules cannot use it.

Can GH secretagogues help with recovery or body composition?

Some studies have looked at these outcomes, but the evidence is limited and inconsistent. These compounds may support certain goals in some contexts, yet no one can promise a result, and the decision belongs in a conversation with a clinician.

Does a 'research use only' label mean a product is tested?

No. That label describes how a seller intends the product to be used, not whether its purity, potency, or content has been verified. It also does not replace regulatory review by a health authority.